Hemophilia Markets Poised for Evolution as Competitive Dynamics between Hemlibra (Roche/Genentech) and Altuviiio (Sanofi) Intensify and Hympavzi (Pfizer) Receives Approval, According to Spherix Global Insights
14 oct. 2024 12h33 HE
|
Spherix Global Insights
EXTON, PA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Hemophilia, a genetic disorder that impairs blood clotting, affects thousands of people worldwide. The treatment landscape is rapidly evolving, fueled by...
Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009, PF-06838435/fida, Marstacimab, FLT180a, Concizumab, Fitusiran
27 mars 2024 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, March 27, 2024 (GLOBE NEWSWIRE) -- Hemophilia B Drug Market Size and Share to Grow by 2032, Assesses DelveInsight | Key Emerging Therapies - CSL222, SerpinPC, AskBio009,...
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy
20 juin 2023 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
15 mai 2023 07h05 HE
|
uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio
30 mars 2023 07h30 HE
|
XOMA Corporation
EMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the commercial payment and a portion of the milestone rights to IXINITY®...
uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
23 févr. 2023 08h05 HE
|
uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for...
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B
21 févr. 2023 07h05 HE
|
uniQure Inc.
~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the...
uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B
16 déc. 2022 07h15 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure announces FDA approval of first gene therapy for adults with hemophilia B
22 nov. 2022 16h40 HE
|
uniQure Inc.
~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX...
Global Hemophilia Gene Therapy Market to Surpass US$ 2,197.9 Million by 2030, Says Coherent Market Insights (CMI)
24 août 2022 08h40 HE
|
CMI
Seattle, Aug. 24, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global hemophilia gene therapy market is estimated to be valued at US$ 330.9 million in 2022 and is expected to...